A Phase IIa Clinical Trial on TSG-01 in the Treatment of Chronic Heart Failure in Patients With Coronary Heart Disease
Latest Information Update: 03 May 2023
At a glance
- Drugs TSG-01 (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Sponsors Shanghai Hongyitang Biopharmaceutical Technology
- 06 Mar 2023 Results presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation
- 24 Oct 2022 Status changed from recruiting to completed.
- 23 Sep 2021 Planned End Date changed from 7 May 2021 to 7 May 2022.